News & Updates
Filter by Specialty:
Show Multimedia Only

Lenacapavir serves its PURPOSE in young individuals
11 Aug 2025
byAudrey Abella
Twice-yearly subcutaneous (SC) lenacapavir demonstrates high efficacy, favourable safety, and consistent pharmacokinetics (PK) as pre-exposure prophylaxis (PrEP) for HIV-negative youth (aged 16–25 years) in an analysis of the phase III PURPOSE 1 (P1) and PURPOSE 2 (P2) trials.